Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$296.80K$296.80Kderived+90.6% vs Q4 2017 Net Income-$14.52K-$14.52KderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$156,650+168.6% Operating Incomederived-$15,551N/M Operating Cash Flowderived$9,003N/M Free Cash Flowderived-$21,741N/M Margins · derivedGross margin52.8%+15.3 pt vs Q4 2017
Operating margin-5.2%+63.8 pt vs Q4 2017
Net margin-4.9%+60.6 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 29, 2019 · 88 d after period end